Hello, Fool! | Login | Signup | My Fool
Oct 6, 2008 10:22 AM ET | Feedback | Site Changes | Help
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
View All Commentary (RGEN)
Recs
Matigrje (53.40) Submitted: 5/21/08 11:24 PM : Start Price: $5.91 RGEN Score: -3.94
Small medical research company that is one of the leaders in finding treatments for bi-polar disorders. Stock price is low with room to climb.
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK